Building the next generation of neurotherapeutics for dementia.
Synthetic cannabinoid medicines designed to address the most challenging neuropsychiatric symptoms of neurodegenerative disease.
The program, at a glance.
Built for investors and partners who scan first and read second.
SynBD™ is an investigational candidate. Its safety and efficacy have not been established and are the subject of the planned study.
A large, poorly-served problem meeting a differentiated approach.
Massive unmet need
More than 55 million people worldwide live with dementia. Behavioural and psychological symptoms affect the majority of patients and remain poorly managed by existing medicines.
Differentiated science
A synthetic cannabidiol engineered without THC exposure, agricultural variability, or plant-derived supply constraints — built for the consistency a clinical program demands.
Clinical validation pathway
Grounded in the established preclinical and clinical literature on cannabidiol, and advancing toward one of the largest synthetic-CBD dementia studies globally.
Commercial opportunity
Targeting one of the largest and fastest-growing segments of neurodegenerative healthcare — an APAC dementia pharmaceutical and care-services market measured in the tens of billions.
The case for engineering the molecule, not harvesting it.
The synthetic route is the foundation of the enterprise — it is what makes SynBD a pharmaceutical asset rather than a botanical product.
Pharmaceutical consistency
Manufactured to pharmaceutical-grade standards, free from plant contaminants and batch-to-batch variability.
Regulatory simplicity
No THC exposure and no cannabis-plant source — designed to improve acceptability with regulators and clinicians.
Scalable manufacturing
Independent of agricultural cultivation cycles, weather and crop-supply constraints — a manufacturable, ownable supply chain.
Global market access
A clean IP and compliance profile, designed for future international regulatory pathways rather than local cannabis restrictions.
Synthetic cannabidiol, engineered for the clinic.
SynBD™ is a nature-equivalent cannabidiol built from citrus-derived terpenes — bio-identical to natural CBD, without the plant. No THC, no batch variability, no botanical contaminants, no licensing baggage.
- 100% bio-identical, zero THC — free from impurities and psychoactive effects.
- Nano-emulsion delivery — engineered for high, consistent absorption.
- Fixed-dose water-soluble vegan capsules — designed for consistent, simplified dosing.
- Built to GMP and Halal standards — manufacturing designed for regulatory acceptance.
- Clean IP profile — no cannabis-plant source, fewer legal and licensing complications.
Built to the clinical gold standard.
SynBD's pivotal study is a multicentre, randomised, double-blind, placebo-controlled trial conducted under ICH-GCP — intended to be the largest study globally evaluating a synthetic CBD therapeutic candidate for dementia, in collaboration with Universiti Putra Malaysia (UPM).
Measured against validated, standardised endpoints:
The regulatory path for a pharmaceutical cannabidiol is no longer theoretical. A plant-derived CBD medicine has already been approved by the US FDA (2018) and the UK MHRA for clinical use. SynBD applies that same pharmaceutical rigour — synthetically and THC-free — to an indication no one has yet owned. Precedent refers to third-party approved products and is not a representation about SynBD, which remains investigational.
A clear line from molecule to market.
Formulation
Synthetic, fixed-dose SynBD™ characterised.
Preclinical
Preclinical groundwork and rationale established.
Ethics & Regulatory
Ethics review in final stages; sites pre-identified.
Phase 3 Trial
Pivotal multicentre RCT; recruitment-ready.
Real-World Evidence
Health-economic and outcomes data generation.
Partnering & Commercial
Licensing and regional market access.
Sites pre-identified and partners engaged — positioned to begin patient recruitment on funding.
A regulatory milestone many early-stage trials are years away from.
Experienced CRO oversight in a cost-efficient setting — materially de-risked versus typical clinical-stage profiles.
Geography as a strategic advantage — not a limitation.
The program is built where serious clinical research can be run faster, more affordably, and across a uniquely diverse population.
Clinical research efficiency
Internationally trained investigators and strong clinical infrastructure, at a fraction of the trial cost of Western markets.
Diverse patient population
A multi-ethnic population supporting broader translational insight and globally relevant data.
Regional gateway
Positioned at the centre of ASEAN — one of the world's most rapidly ageing populations.
Clinical depth and commercial discipline, in one room.
Investigators from leading neuroscience and dementia research, alongside operators who have built healthcare businesses across the APAC region.
Dr Donald Cooper
PhD Neuroscience (Chicago Medical School); postdoctoral fellow in neurophysiology at Northwestern. 45+ papers in journals including Science and Nature Neuroscience, 9,000+ citations, and 7 US patents — including cannabinoid-coated nanocapsule delivery.
Assc. Prof. Dr Aris Moklas
PhD Neuroscience (University of Nottingham). Research focused on neuronal plasticity and neurobehavioural adaptation in models of adult-onset neurodegenerative disease relevant to Alzheimer's and Parkinson's.
Dr Nurul Huda Mohd Nor
MBBS (University College Dublin), PhD Anatomy (UPM). Medical lecturer in Human Anatomy at UPM, with research in neurosciences, atherosclerosis, thrombosis and cardiovascular disease.
Jonathan Lee
A health, wellness and fitness portfolio spanning professional training and premium equipment markets. Leads APAC market-entry strategy for pharmaceutical companies.
Simone Lee
LL.B (Bristol), Barrister-at-Law (Middle Temple, non-practising). 28+ years in pharmacy healthcare, driving the shift to value-based care with pharmacists as central stakeholders in prevention and chronic-disease management.
A company, not a project.
SynBD™ is the lead program of a clinical-stage neurotherapeutics company, backed by investigators, regulators and operators across the region.
One lead program. A broader platform behind it.
SynBD™ is the lead program in a broader synthetic cannabinoid research platform exploring neurodegenerative and age-related neurological disorders — optionality beyond a single indication.
Research & co-development partnering
Investigating a new indication in synthetic cannabinoids? We co-develop and license platform assets with academic groups, clinicians and capital partners — you bring the indication, we bring the THC-free molecule, GMP manufacturing and clinical infrastructure.
Areas beyond dementia are exploratory research directions, not active clinical programs. SynBD™ is an investigational candidate.
Open to the partners who build category leaders.
We are engaging a select group of strategic and capital partners to advance SynBD™ and the platform behind it.
Strategic pharma & licensing
Regional and global pharmaceutical partners seeking differentiated, clean-IP neurotherapeutic assets and licensing opportunities.
Clinical & academic collaboration
Research institutions, investigators and CROs extending the evidence base across neurodegenerative and age-related disorders.
Capital partners
Family offices, institutional investors and sovereign funds backing a clinical-stage company with platform optionality and regional advantage.
Back a category-defining neurotherapeutics company.
The confidential briefing — covering the clinical program, regulatory pathway, platform and terms — is available on request to qualified investors and strategic partners.
Talk to us.
Jonathan Lee — Director
jonathanlee@purelife-pharma.com
+65 9877 7720
Simone Lee — Research Director
simone@purelife-pharma.com
+60 12 631 2788
For investor and partnering enquiries, please use the Investor Relations request form.